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Background: Preeclampsia (PE) is a pregnancy-related vascular disorder which is the leading cause of maternal
morbidity and mortality. We sought to identify novel serological protein markers to diagnose PE with a multi-’omics’
based discovery approach.
Methods: Seven previous placental expression studies were combined for a multiplex analysis, and in parallel,
two-dimensional gel electrophoresis was performed to compare serum proteomes in PE and control subjects. The
combined biomarker candidates were validated with available ELISA assays using gestational age-matched PE
(n=32) and control (n=32) samples. With the validated biomarkers, a genetic algorithm was then used to construct
and optimize biomarker panels in PE assessment.
Results: In addition to the previously identified biomarkers, the angiogenic and antiangiogenic factors
(soluble fms-like tyrosine kinase (sFlt-1) and placental growth factor (PIGF)), we found 3 up-regulated and 6
down-regulated biomakers in PE sera. Two optimal biomarker panels were developed for early and late onset PE
assessment, respectively.
Conclusions: Both early and late onset PE diagnostic panels, constructed with our PE biomarkers, were superior
over sFlt-1/PIGF ratio in PE discrimination. The functional significance of these PE biomarkers and their associated
pathways were analyzed which may provide new insights into the pathogenesis of PE.
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As the leading cause of maternal morbidity and mortality,
preeclampsia (PE) is a pregnancy-related vascular disorder
affecting 5% to 8% of all pregnancies [1,2]. PE, which often
associates with fetal growth restriction and pre-term deliv-
ery as well as fetal mortality and morbidity, can be remed-
ied by delivery of the placenta and fetus [3]. The etiology of
PE is incompletely understood. Current diagnosis of PE is
based on the signs of hypertension and proteinuria [4], but
lacks sensitivity and specificity and carries a poor prognosis
for adverse maternal and fetal outcomes [5]. Thus, there is
a need to identify PE biomarkers that can provide a defini-
tive diagnosis with the opportunity for better monitoring of* Correspondence: bxling@stanford.edu; abutte@stanford.edu
†Equal contributors
2Department of Surgery, Stanford University, Stanford, CA 94305, USA
1Department of Pediatrics, Stanford University, 1265 Welch Road, Room X-163
MS-5415, Stanford, CA 94305, USA
Full list of author information is available at the end of the article
© 2013 Liu et al.; licensee BioMed Central Ltd.
Commons Attribution License (http://creativec
reproduction in any medium, provided the orthe condition’s progression and, thus, improved outcomes
and economic benefits.
Although the pathophysiology remains largely elusive,
PE is a multisystem disorder of pregnancy with the placenta
playing a pivotal role. Investigators have used genetic,
genomic and proteomic approaches to compare PE and
control placental tissues. Transcriptional profiling of case–
control samples has identified disease-specific expression
patterns, canonical pathways and gene-gene networks
[6-12]. Proteomics-based biomarker studies [13-15] have
also revealed candidate biomarkers for future testing.
Placental angiogenic and anti-angiogenic factor imbal-
ance, elevated soluble fms-like tyrosine kinase (sFlt-1)
and decreased placental growth factor (PIGF) levels
are suggested in the pathogenesis of PE [16-22], and
the sFlt-1/PIGF ratio has been proposed as a useful
index in the diagnosis and management of PE [23,24].
However, no widely applicable, sensitive and specificThis is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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rently available.
In light of these considerations, there is a strong rationale
and need to discover diagnostic biomarkers for PE. It is
likely unrealistic that a single biomarker could be used to
diagnose multifactorial diseases such as PE. Therefore,
we employed a comprehensive unbiased multi-’omics’
approach, integrating results from microarray multiplex
analysis and proteomic identification by two-dimensional
gel analysis. Our applied parametric method [25,26]
allowed us to identify consistent and significant differential
gene expression across experiments to develop biomarkers
for downstream experimental validation. Serum proteins
are routinely used to diagnose diseases, but sensitive
and specific biomarkers are hard to find; this may be
due to their low serological abundance, which can easily be
masked by highly abundant proteins. Our serum protein
marker discovery method [27] combines antibody-based
serum abundant protein depletion and two-dimensional
gel comparative profiling to discover differential protein
gel spots between PE and control sera for subsequent
protein mass spectrometric identification. We hypothesized
that there would be differential serological signatures
allowing PE diagnosis. To validate our discovery find-
ings, we tested all the candidates with available ELISA
assays, a higher-throughput method. To construct and
optimize a sensitive and specific biomarker panel with the
least number of protein analytes, a genetic algorithm was
used. Close examination of the biomarkers from compara-
tive transcriptomics and proteomics, and their associated
pathways led to new hypothesis about their role in PE
pathophysiology.
The results validated our hypothesis that sensitive and
specific serological biomarker panels can be constructed to
diagnose PE. To our knowledge, this represents the first
study to employ a muti-’omics’-based biomarker approach
to uncover novel PE biomarkers superior to sFlt-1, PIGF,
and the sFlt-1/PIGF ratio in PE discrimination. We believe
that the functional significance of these PE biomarkers
and their associated pathways will provide new insights




All the serum samples were purchased from ProMedDX
Inc. (Norton, MA, USA, http://www.promeddx.com) and
included detailed case report forms. We confirmed with
ProMedDX that all of the ProMedDX specimens we used
were collected under Institutional Review Board approved
protocols by qualified Investigator sites. These sites
conducted ProMedDX studies according to 21 CFR,
ICH/GCP guidelines and HIPAA Privacy Regulations.
Informed consent was obtained from every subject,unless this requirement had been determined by the
IRB not to apply and had been waived.Study design
The overall sample allocation, PE biomarker discovery,
validation and diagnostic panel construction steps are
illustrated in Figure 1. Our study was conducted in two
phases: (1) the discovery phase, which included both the
in silico expression analysis (n = 111 PE and n = 152 con-
trol placenta samples) and the proteomics two-dimensional
gel profiling (pooled n = 5 PE and pooled n = 5 control
serum proteomes); and (2) the validation phase, which
comprised the analysis of independent PE (n = 32) and
control (n = 32) cohorts. All the serum samples were
purchased from ProMedDX Inc. All serum samples
were collected after informed consent was obtained and in-
cluded detailed case report forms. Excluded from this study
were patients who were current smokers, had a history
of substance abuse, used in vitro fertilization assistance,
had chronic hypertension and pregnancies complicated
by intrauterine growth restriction. Case (PE) and control
(normal pregnant) cohorts were matched for gestational
age, ethnicity and parity.Multiplex analysis of expression comparing preeclampsia
and control placentas
As shown in Additional file 1: Table S1, seven PE pla-
centa expression studies [7,10-12,28,29] were combined
and subjected to multiplex analysis with the method we
previously developed [25,26]. For each of the 22,394
genes tested, we calculated the meta-fold change across
all studies. For gene expression measurements, this cor-
responds to combining fold-changes across studies to
identify a meta-fold-change that is an amalgamation of
the constituent studies. We took a linear combination
of effect sizes (fold-changes in this case), weighted by
the variance in the effect size within each study, with
the confidence intervals combined with the same weights.
This means that studies with larger intra-study vari-
ation (noise) contribute less to the overall estimate of
fold-change. The meta p-values were obtained by Fish-
er’s method. Significant genes were selected if they
were measured in five or more studies and the meta ef-
fect p value was less than 4.5 × 10-5. We then filtered
the gene sets through a list of 3,638 proteins with
known detectable abundances in sera, plasma, or urine
[30]. The 3,638 protein list was created from public
sources [31-34] and has been described [30]. This ef-
fort yielded a set of candidate protein biomarkers. At
every step of the data mining processes, a biomarker
specialist manually curated candidates to provide qual-
ity control and prioritize the candidates for the subse-
quent validation studies.
Figure 1 Study outline of the multi-’omics’-based discovery and validation of PE biomarkers. Candidate analytes, which failed subsequent
validation, are greyed out. PE, preeclampsia.
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preeclampsia and control patient serum samples
To enrich samples for lower abundance serum pro-
teins, serum samples were depleted of the top fourteen
serum-abundant proteins (albumin, immunoglobulin
G (IgG), antitrypsin, IgA, transferrin, haptoglobin, fibrino-
gen, alpha2-macroglobulin, alpha1-acid glycoprotein, IgM,
apolipoprotein A-I, apolipoprotein A-II, complement C-III
and transthyretin) using the Agilent Multiple Affinity
Removal System (Agilent, Santa Clara, CA, USA). Spe-
cifically, the depletion enabled the increased loading of
the remaining proteins by fifteen-fold [27]. Further sam-
ple processing, two-dimensional gel electrophoresis,
comparative analysis, and differential gel spot protein
identification via mass spectrometry was performed as
previously described [27].
ELISA assays validating preeclampsia marker candidates
All assays were ELISA assays and were performed using
commercial kits following the vendors’ instructions.
All assays were performed to measure serum levels of
selected analytes: alpha-2-macroglobin (A2M, Abnova
Inc.,Taipei, Taiwan); disintegrin and metalloproteinase
domain-containing protein 12 (ADAM12, Mybiosource,
San Diego, CA, USA); adipophilin (ADRP, Biotang Inc.,
Waltham, MA, USA); apolipoprotein (APO) A-I (Abcam
Inc., Cambridge, MA, USA); apolipoprotein (APO) C-III
(Abnova); apolipoprotein (APO)-E (Abcam); cathepsin B
(CTSB, Abcam); cathepsin C (CTSC, USCN Life Science,
Wuhan, China); chemokine (C-C motif) ligand 2 (CCL2)
(Abnova); haptoglobin (HP, Abcam); hemopexin (HPX,Abcam); PIGF (R&D Systems, Inc., Minneapolis, MN,
USA); heme oxygenase 1 (HMOX1, Biotang); insulin-
like growth factor binding protein 7 (IGFBP7, USCN Life
Science); keratin 33A (KRT33A, USCN Life Science);
keratin 40 (KRT40, USCN Life Science); kininogen 1
(KNG1, Abcam); pikachurin (EGFLAM, EIAab Science,
Wuhan, China); pro-platelet basic protein (PPBP, Abnova);
retinol-binding protein 4 (RBP4, Abcam); and sFlt-1
(R&D Systems).
Statistical analyses
Patient demographic data were analyzed using the
‘Epidemiological calculator’ (R epicalc package). Student’s
t test was performed to calculate p values for continuous
variables, and Fisher’s exact test was used for comparative
analysis of categorical variables. Forest plotting with the
R rmeta package was used both to represent the placental
expression meta analysis and to graphically summarize
the serum protein ELISA results. Case (PE) and control
samples are not paired; thus, the initial serum protein
forest plot analysis should be interpreted with caution.
The bootstrapping method was used to create ‘paired’
samples from case and control groups for the subsequent
forest plotting analysis of the ELISA results. Therefore,
serum protein forest plot analysis provides an overall effect
estimation of each analyte’s capability in discriminating
PE and normal pregnant control subjects. Hypothesis
testing was performed using Student’s t-test (two tailed)
and the Mann–Whitney U-test (two tailed), and local false
discovery rate (FDR) [35] to correct for multiple hypoth-
esis testing issues. Biomarker feature selection and panel
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(R genalg package). The diagnostic performance of each bio-
marker panel analysis was evaluated by receiver operating
characteristics (ROC) curve analysis [36,37]. The biomarker
panel score was defined as the ratio between the geometric
means of the respective up- and down-regulated protein
biomarkers in the maternal circulation.
Results
Multi-’omics’-based discovery revealing preeclampsia
marker candidates
As shown in Figure 1, previous placental expression
studies were combined for a multiplex analysis to discover
biomarker candidates that could be used to diagnose
PE from normal controls. This effort identified A2M,
ADAM12, CCL2, CTSB, CTSC, EGFLAM, HOMX1,
IGFBP7, KRT33A, KRT40, PIGF, PPBP and sFlt-1 as
differential placental biomarkers for PE. In parallel, two-
dimensional gel analysis was performed to compare sero-
logical PE and control pooled proteomes, revealing highly
discriminating protein spots that were later sequenced. The
two-dimensional gel profiling led to the identification of
A2M, ADFP, APO A-I, APO C-III, APO-E, KNG1, HP,
HPX and RBP4 marker candidates.
Sample characteristics
The PE and control subjects used for serological protein
biomarker validation can be divided into early (PE, n = 15;
control, n = 16) and late (PE, n = 17; control, n = 16)
gestation groups. As summarized in Tables 1 and 2, no
significant differences in age (p value, early 0.89, late
0.857, overall 0.6), gestational age (p value, early 0.851, late
0.895, overall 0.824) at enrollment, ethnicity (p value, early
0.57, late 0.123, overall 0.289), or subjects’ concurrent
medical conditions and other clinical features (p value,





Number = 15 (48.4%) Number = 16 (51.6%)
Ethnicity 0.57
African American 5 (33.3%) 5 (31.2%)
Asian 2 (13.3%) 0 (0)
Hispanic 8 (53.3%) 10 (62.5%)
Other 0 (0) 1 (6.2%)
Age (year)
mean (SD) 24.3 (4.5) 24.1 (6.1) 0.89
Week of gestationa
mean (SD) 30.3 (3.2) 30.1 (2.9) 0.85
aThe time of blood drawing. PE, preeclampsia.The PE patients were diagnosed with preeclampsia char-
acterized by both hypertension and proteinuria. As shown
in Table 3, all of the 32 PE patients had both hypertension
and proteinuria; 43.8% of them had headache; 21.9% of
them had edema; and 25.0% of them had other additional
symptoms. Other characteristics, including body mass
index (BMI, prior to pregnancy), blood pressure (BP),
protein/creatinine ratio (PCR) and pregnancy history
are also shown in Table 4.
Biomarker validation using preeclampsia and control
maternal serum samples
To identify whether the PE serological protein panel could
enable development of an immediate practical clinical tool,
based on available ELISA assays, biomarker candidates,
from expression multiplex analysis and two-dimensional
gel profiling, were validated with available serum assays
using PE (n = 32) and gestation age-matched control
samples (n = 32). Detailed with whisker box and scatter
plots in Additional file 2: Figure S1-(1 through 11), a
total of 11 proteins were validated by ELISA assays
(Mann–Whitney tests p value <0.05). Each validated
biomarker’s median, mean and standard deviation of
maternal serum abundance, in PE and control sam-
ples, are summarized in Table 5.
Forest plots (Figure 2) summarize the PE to control ratios
of all 11 validated PE markers across placental expression
multiplex analyses, and early and late gestation mater-
nal serum analyses. The biomarkers derived from the
proteomic and expression analyses consistently shared
the same trend of up- or down-regulation between PE
and control samples.
Preeclampsia biomarker panel construction
Using data from the ELISA assays, we constructed different
panels with various subsets of the assays. We sought toLate stage Overall
ue
PE Control
p value p value
Number = 17 (51.5%) Number = 16 (48.5%)
0.123 0.289
2 (11.8%) 4 (25%)
0 (0) 0 (0)
11 (64.7%) 12 (75%)
4 (23.5%) 0 (0)
27.9 (9.0) 26.6 (7.7) 0.857 0.6
1 37.1 (1.4) 37.2 (1.6) 0.895 0.824




n = 32 (50%) n = 32 (50%)
Concurrent medical conditions/Clinical features 0.35
Anemia 0 (0) 2 (6.2%)
Asthma, other: chlamydia (2009) 1 (3.1%) 0 (0)
Asthma, other: Group B streptococcus carrier, maternal deficiency anemia, thrombocytopenia 1 (3.1%) 0 (0)
Crohn’s disease 0 (0) 1 (3.1%)
Diabetes - Type II 2 (6.2%) 1 (3.1%)
Diabetes - Type II, morbid obesity, other: history of depression 1 (3.1%) 0 (0)
Diabetes - Type II, other: left breast lump 1 (3.1%) 0 (0)
Diabetes (gestational) 1 (3.1%) 3 (9.4%)
Diabetes (gestational), obesity 1 (3.1%) 0 (0)
Fatty liver 1 (3.1%) 0 (0)
Hyperthyroidism 1 (3.1%) 0 (0)
Migraines, urinary tract infection (UTI) 1 (3.1%) 0 (0)
None 19 (59.4%) 24 (75%)
Other: borderline gestational diabetes 1 (3.1%) 0 (0)
Other: hepatitis C antibody = reactive 0 (0) 1 (3.1%)
Other: history of cardiac surgery at birth, marginal cord insertion 1 (3.1%) 0 (0)
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ancing the need for small panel size, accuracy of classifica-
tion, goodness of class separation (PE versus control), and
sufficient sensitivity and specificity. With the aim of devel-
oping a multiplexed antibody-based assay for PE diagno-
sis, we used a genetic algorithm method to construct
biomarker panels from the nine validated PE protein bio-
markers for early and late gestational age PE, comparing
to the sFlt-1/PIGF ratio in assessing PE. The algorithm
guided panel construction processes, leading to early and
late gestational age biomarker panels, which had complete
separation between PE and control subjects (Table 6).
These chosen biomarker panels are non-redundant, indi-
cating non-inclusive relationships. The sFlt-1/PIGF ratio’s
PE assessment utility (panel 0: early onset, ROC area under
the curve (AUC) 1.00, p value 4.35 × 10-4; late onset, ROC
AUC 0.86, p value 2.94 × 10-4; Additional file 2: Figure S3),
previously through the multicenter trial validation [24], was
confirmed in this study and used as a benchmark for our
newly derived biomarker panels. Panel 1 (early onset, ROCTable 3 PE patients’ presenting signs and symptoms






PE, preeclampsia.AUC 1.00, p value 1.43 × 10-4) has three proteins, HPX,
APO A-I and pikachurin. Panel 2 (late onset, ROC AUC
1.00, p value 3.65 × 10-5) has six proteins, HPX, HP, APO
C-III, APO A-I, RBP4 and pikachurin. To demonstrate the
efficacy of the biomarker panel as a classifier for PE disease
activity according to disease onset, the biomarker panel
scores were plotted as a function of time of the gestational
age (composite summary in Additional file 2: Figure S2,
details shown in Figure 3). According to the scatter plot
analysis, the performance of our early-onset PE biomarker
panel was comparable to the sFlt-1/PIGF ratio. For ges-
tational age >34 weeks samples, performance of our bio-
marker panel is better than the sFlt-1/PIGF ratio that
has several errors of diagnosis around week 36. Among
the early and late gestational age biomarker panels,
HPX, APO A-I, and pikachurin are present in both
panels, indicating their critical role in the diagnosis.
Pathway analysis of PE biomarkers
We analyzed the validated biomarkers that are significantly
differentially expressed in PE as a composite, using Ingenuity
Pathway Analysis software (IPA version 7.6, Ingenuity
Systems, Inc., Redwood City, CA, USA). In addition to the
heme/hemoglobin degradation pathway revealed during
our multi-’omic’ discovery effort, our pathway analysis led
to the identification of the following statistically significant
canonical pathways which may play important roles in PE
pathophysiology: liver X receptor (LXR)/retinoid X receptor
(RXR) activation, p value 5.13 × 10-9; atherosclerosis sig-
naling, p value 5.01 × 10-7; IL-12 signaling and production in
Table 4 PE patients’ clinical information
Characteristics Statistics
BMI (prior to pregnancy) (kg/m2) 29.1 (23.0, 33.9)
Systolic blood pressure 146.0 (134.0, 157.5)
Diastolic blood pressure 85.5 (77.0, 94.5)
Protein/creatinine ratio (PCR) test results (mg/g) 803.5 (449.5 to 1492.0)
Prior history of preeclampsia
Yes 3 (9.4%)
No 28 (87.5%)




Number of abortions (induced or spontaneous)
number = 0 21 (65.6%)
number = 1 5 (15.6%)
number = 2 2 (6.2%)
number = 3 2 (6.2%)
number = 4 0 (0%)
number = 5 1 (3.1%)
number = 6 1 (3.1%)
Number of full term pregnancies
number = 0 22 (68.8%)
number = 1 2 (6.2%)
number = 2 3 (9.4%)
number = 3 3 (9.4%)
number = 4 1 (3.1%)
number = 5 1 (3.1%)
Number of premature pregnancies
number = 0 27 (84.4%)
number = 1 4 (12.5%)
number = 2 1 (3.1%)
Smoking history
Never 32 (100%)
Total number of pregnancies
number = 1 14 (43.8%)
number = 2 4 (12.5%)
number = 3 5 (15.6%)
number = 4 4 (12.5%)
number = 5 2 (6.2%)
number = 6 1 (3.1%)
number = 7 0 (0%)
number = 8 0 (0%)
number = 9 0 (0%)
number = 10 1 (3.1%)
number = 11 1 (3.1%)
Table 4 PE patients’ clinical information (Continued)
In vitro fertilization (IVF) utilized
for this pregnancy
No 32 (100%)
BMI, systolic blood pressure, protein/creatinine ratio (PCR) – Median
(Interquartile range).
BMI, body mass index; PE, preeclampsia.
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signaling, p value 1.91 × 10-6; production of nitric oxide
and reactive oxygen species in macrophages, p value
2.82 × 10-6; clathrin-mediated endocytosis signaling, p value
2.88 × 10-6; farnesoid X receptor (FXR)/RXR activation,
p value 2.04 × 10-5; hepatic fibrosis/hepatic stellate cell
activation, p value 2.88 × 10-3; phosphatidylethanolamine
biosynthesis II, p value 1.05 ×10-2; coagulation system,
p value 2.04 × 10-2; growth hormone signaling, p value
4.27 × 10-2; reelin signaling in neurons, p value 4.57 × 10-2;
and VEGF family ligand-receptor interactions, p value
4.79 × 10-2.Discussion
We have applied a multi-’omics’ approach to develop
validated PE biomarkers, integrating discoveries from
placental mRNA expression multiplex analysis and depleted
serological proteome two-dimensional gel comparative
profiling. Comparing PE and control sera with com-
mercially available ELISA assays, we have validated 11
protein markers, including sFlt-1 and PIGF, and found
that our identified PE biomarkers were superior over
the sFlt-1/PIGF ratio in diagnosing PE. The concept of
combining a transcriptomic approach in placenta tis-
sue with a proteomic approach in serum is novel. It
combines the advantages of a study in tissue which is
closer to the focus of the pathophysiology with those
of a study in serum which is more appropriate for clin-
ical use. Taking proteins that have been discovered
from the discovery phase to an ELISA-based validation
phase makes the findings of this study translatable into
clinical practice.
When comparing the discoveries from expression multi-
plex analysis and two-dimensional gel serum proteomics,
only A2M showed up in both analyses. This could be due
to the following reasons: (1) the discordant expression
of protein and mRNA as previously characterized [38-41];
(2) the lack of translation of the placental expression
into circulation protein level abundance; and (3) two-
dimensional gel technology detection limit of 0.5 to 5
ng. The optimized two-dimensional gel technique has
a dynamic range of approximately five orders of magni-
tude in protein concentration [42], whereas serological
protein concentrations vary over approximately ten orders
of magnitude, with the highest concentrations reaching
Table 5 Maternal serum levels of the validated PE biomarkers
Analyte PEtrend Unit
Early stage Late stage
Normal PE Normal PE
Median Mean Median Mean Median Mean Median Mean
(IQR) (SD) (IQR) (SD) (IQR) (SD) (IQR) (SD)
PIGF ↓ pg/ml 413.8 529.4 97.5 115.5 222.279 238.1095 184.488 202.6929
(224.9, 685.2) (432.0) (51.6, 190.7) (83.0) (163.6, 289.9) (111.5) (113.2, 223.8) (132.7)
sFlt-1 ↑ pg/ml 1697.9 3034.0 19841.3 18646.3 5610.460 5531.241 14216.20 14414.28
(1128.2, 4273.9) (2578.7) (15728.4, 21608.6) (3582.5) (4191.8, 6735.8) (1811.9) (12347.6, 19749.3) (5575.3)
HPX ↑ ug/ml 1071.2 984.1 1382.8 1580.7 954.4 894.15 1482.0 1347.624
(692.4, 1301.0) (388.3) (1173.6, 1787.0) (546.5) (538.0, 1131.6) (331.5) (1013.6, 1654.4) (585.3)
ADAM12 ↑ pg/ml 511.3 584.0 775.0 920.2 666.4185 703.6862 883.889 1345.369
(437.7, 642.3) (275.8) (637.2, 1150.2) (416.4) (594.9, 791.8) (217.2) (626.7, 1367.6) (1472.5)
APO C-III ↓ ng/ml 341.3 364.7 419.2 486.3 291.58 321.8587 453.789 585.7512
(249.5, 422.4) (153.4) (357.3, 575.5) (187.5) (240.7, 345.7) (126.7) (308.9, 725.8) (413.1)
HP ↓ ug/ml 1624.1 1718.0 1181.6 1482.7 1806.74 1750.72 985.616 1510.514
(1216.0, 2274.1) (764.1) (684.6, 1794.1) (1284.6) (1190.1, 2163.1) (684.1) (592.0, 1880.8) (1515.0)
A2M ↓ ug/ml 5796.4 5729.1 3365.1 4259.3 8141.38 7754.764 3435.427 4340.768
(3501.2, 7737.6) (3064.1) (2648.3, 9959.0) (2175.8) (5300.6, 10234.1) (3265.1) (2343.7, 6752.9) (2862.5)
APO-E ↓ ug/ml 290.6 364.4 138.8 215.9 398.0 377.9 147.2 150.0235
(104.2, 519.0) (301.5) (63.0, 210.4) (257.6) (125.0, 478.4) (236.3) (60.4, 190.0) (107.7)
APO A-I ↓ ng/ml 7980.1 8337.7 4945.356 4708.5 6253.298 6748.614 4724.142 5483.643
(5775.7, 11076.6) (3158.7) (3892.8, 5824.6) (1707.1) (5624.1, 7881.8) (2287.6) (3138.6, 7075.3) (3794.9)
RBP4 ↓ ng/ml 38255.0 35180.4 38899.0 36931.7 41616.5 49253.5 33179 33897.47
(29018.5, 40955.5) (7031.1) (33460.5, 39895.0) (7307.5) (38830.5, 44429.5) (38081.6) (29558, 37386) (8499.8)
pikachurin ↓ ng/ml 601.8 659.1 293.261 327.8 536.551 536.551 317.657 317.657
(563.8, 792.1) (152.0) (267.4, 367.8) (117.5) (459.2, 626.6) (952.3) (266.8, 409.7) (623.5)
IQR: interquartile range; PE: preeclampsia; SD: standard deviation.
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by our two-dimensional gel is limited to proteins whose
serological concentrations are >10 ug/mL, clearly influ-
encing the composition of the protein biomarkers we
detected. In addition, potentially informative low mo-
lecular weight proteins may bind to albumin and, thus,
be removed at the depletion step [44], which could be a
potential disadvantage. Thus, candidates with pg/mL
concentration, for example, sFlt-1 and PIGF, would not
be found when applying the two-dimensional gel serum
proteomics based approach. Publicly available genome-
wide gene expression data on disease tissues can be
effectively mined to provide significant synergies to
complement our two-dimensional serum proteomics efforts
to unveil differential PE biomarker candidates of low serum
abundance (pg/mL). Notably, our productive PE discovery
efforts support the notion that the multi-’omics’ approach
for biomarker analyses are comprehensive, comple-
mentary and effective in identifying candidates of a
broad dynamic range of serological protein expression,
varying from pg/mL to ug/mL.As summarized in Figure 2, the validated biomarkers’
placental expression, and the early and late gestation
maternal serum analyses revealed a similar trend of up- or
down-regulation between PE and control samples. How-
ever, our study did not explore the extent (percentage) of
the contribution by the placenta or other maternal cells to
the overall differential serum expression between PE and
control subjects. Future expression analysis is needed to
characterize the tissue expression pattern of these PE
markers and their expression kinetics as a function of the
gestational age to understand the tissue specific expression
contribution to the differential serum expression pattern
observed in this study.
Additional pathway analyses of the protein markers
corroborate growing evidence implicating roles for the
lipid homeostasis, IL-12 and coagulation canonical path-
ways in PE pathophysiology. The LXR/RXR activation
pathway was identified as the most significant pathway.
This supports recent findings [45] that PE is associated
with hyperlipidemia and that the regulators of lipid
homeostasis are important in the PE pathophysiology.
Figure 2 Expression comparative analyses of PE biomarkers (PE versus controls). Forest plot summarizes the results of placental mRNA
expression multiplex analysis, and maternal sera analyte abundance quantification at different early and late gestational age weeks. Line plot
represents 95% confidence intervals. PE, preeclampsia.
Table 6 Biomarker panels integrating maternal serum
levels of the validated PE biomarkers
PE onset Early Late
Panel 0 1 0 2
sFlt-1a + - + -
PIGF + - + -
HPXa - + - +
FT - - - -
ADAM12a - - - -
HP - - - +
A2M - - - -
APO-E - - - -
APO C-IIIa - - - +
APO A-I - + - +
RBP4 - - - +
HB - - - -
FGA - - - -
pikachurin - + - +
Panel size 2 3 2 6
ROC AUC 1.00 1.00 0.86 1.00
p value 4.35E-4 1.43E-4 2.94E-4 3.65E-4
aIndicates biomarkers up-regulated in PE. Panel 0 is the benchmark panel
sFlt-1/PIGF ratio; ‘+’, selected in panel; ‘-‘, unselected.
AUC: area under the curve; PE: preeclampsia; ROC: receiver
operating characteristic.
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with less activity in placenta and more abundance in
sera was reflected as in line with our PE biomarker
panel pattern pathway analysis.
A previous multicenter case–control study [24] with an
automated assay, demonstrating the utilities of sFlt-1 and
PIGF for PE assessment, reported serum abundance of sFlt-
1 (PE: 12,981 ± 965 versus control: 2,641 ± 100.5 pg/mL)
and PIGF (PE: 76.06 ± 10.71 versus control: 341.5 ±
13.57 pg/mL). Although with greater variation, possibly due
to different sample cohorts or assay platforms, the trend of
alteration reflected in our results, sFlt-1 (PE: 16,398.02 ±
5,142.32 versus control: 4,282.63 ± 2,532.90 pg/mL) and
PIGF (PE: 161.83 ± 118.98 versus control: 383.75 ± 343.84
pg/mL) was in line with their report. As shown in
Additional file 2: Figure S1 and summarized in Additional
file 1: Table S2, sFlt-1 and PIGF protein abundance differs
significantly between early and late gestational age samples
in both normal (p value: sFlt-1 0.003, PIGF 0.020) and PE
(p value: sFlt-1 0.017, PIGF 0.022) groups. Our bio-
marker [see Additional file 1: Table S2] RBP4 (p value:
normal 0.029, PE 0.176), ADAM12 (p value: normal
0.035, PE 0.777) and pikachurin (p value: normal 0.049,
PE 0.502) differs marginally between early and late ges-
tational age samples in normal (p value <0.05) but not
in PE (p value >0.05) groups. For HPX, APO C-III, HP,
APO-E and APO A1, there was no significant differ-
ence (p value >0.05) between early and late gestation
sera in both normal and PE groups. The sFlt-1/PIGF
ratio was found to be important for the prediction of
Figure 3 Early or late onset biomarker panel scores were plotted as a function of the gestational age. Different panel scores were scaled
to the same scoring metric such that they can be directly compared. For either PE or control data points, a loess curve was fitted to represent
the overall trend of biomarker scoring as a function of gestation. PE, preeclampsia.
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(IUGR) [49]. Therefore, the previous observation of the
sFlt-1 and PIGF expression difference between early
and late onset cases may be due to the recruited sam-
ple difference between early (both IUGR and early PE)
and late (PE only) cases. Given that our sample cohort
excluded IUGR, the serum markers identified in this
study may be more specific to PE rather than to both
IUGR and PE. To summarize, our results here indicate
that sFlt-1 and PIGF are regulated during placental de-
velopment as a function of gestation, and differential
expression between PE and control might be due to
placental adaptation during PE. The PE biomarkers
found in this study are not significantly different be-
tween early and late gestation in either PE or control
sera. Therefore, their differential expression in PE might
directly gauge the disease activity of PE and disease de-
velopment or reflect features that are present at fairly
advanced stages of the pathogenesis, for example, pro-
teinuria and high blood pressure.
Our genetic algorithm-based biomarker panel construc-
tion led to final early and late gestational age biomarker
panels for PE assessment. Compared to the benchmarksFlt-1/PIGF ratio in PE assessment, our biomarker panels
perform comparably during early gestational age but
clearly outperform at later gestational weeks. Although
the sFlt-1 and PIGF imbalance used for PE diagnosis has
been demonstrated, there is mounting evidence to support
the notion that normal sFlt-1 and PIGF expression actually
characterizes healthy pregnancies [50]. Therefore, sFlt-
1 and PIGF may really be general markers for failed
pregnancies, for example, ectopic pregnancies, missed
abortions, rather than specific to PE. Our multi-’omics’
approach discovered panels of multiple biomarkers, reflect-
ing the multifaceted aspects of PE disease, and have the po-
tential both to provide a definitive diagnosis of PE patients
and to be used to monitor disease progression.
We also recognize several limitations to our study.
Samples were collected after the clinical diagnosis of
PE with disease onset. The outcome information after
the sample collection, including the time of delivery,
and the birth weight and growth percentile of the babies,
is not available. Therefore, the biomarker panels’ utility in
risk patient identification remains to be demonstrated.
Nevertheless, confirmatory diagnosis is also valuable as it
has the benefit of objective diagnosis, reducing over and
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to clinics, a clinical trial of the prospective cohort design
is needed. As one of the limitations of this study, we used
commercially available ELISA kits, the antibodies of which
may cross-react with other homologous proteins. For ex-
ample, the R&D sFlt-1 ELISA kit antibodies can recognize
both sFlt-1 and full trans-membrane VEGF-R1, as well. To
support future prospective trials to test the clinical utility of
our PE panel, analyte specific antibody reagents may need
to be developed.
Although preeclampsia is diagnosed when a pregnant
woman develops both elevated blood pressure and
proteinuria, these symptoms tend not be specific and
preeclampsia can be asymptomatic as well. Therefore,
the clinical definition alone is insufficient to predict
adverse maternal and/or neonatal outcomes [51,52] caused
by preeclampsia. Previous prospective cohort studies have
found the utility of the elevated sFlt1/PIGF ratio in the pre-
diction of the subsequent adverse maternal and prenatal
outcomes within two weeks [53]. The scatter plot analysis
(Figure 3) as a function of gestational age suggests that, for
our early onset panel, the best performance in PE assess-
ment was obtained near 24 to 25 weeks when comparing
to gestation towards 34 weeks. Certain changes in our
biomarker panel of serum protein profiles may occur at
the first trimester and in advance of clinically-detectable
PE disease activity. Thus, we hypothesize that our PE
biomarkers can predict impending PE disease activity,
and/or adverse outcomes in pregnant women with sus-
pected preeclampsia, especially in a pre-specified group
of patients presenting at less than 24 weeks gestation.
To test these hypotheses, future prospective cohort studies
will be required to address the potential clinical usefulness
of our PE biomarkers in predicting impending PE or ad-
verse maternal and/or neonatal outcomes.
Additional files
Additional file 1: Table S1. Expression data sets used for multiplex
meta analysis based PE marker discovery. Table S2. Comparison of
biomarker’s abundances at early and late gestational age time points.
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biomarker distributions at different gestation in PE and control groups.
Horizontal box boundaries and midline denote sample quartiles. Figure S2.
Composite overlay of different biomarker panels’ loess fitted lines for
both PE and control subjects as a function of gestation. Figure S3. The
performance, gauged by ROC analyses, of PE serum protein biomarker
panel 0, 1, and 2 in discriminating PE and control subjects.
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